Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous hepatic arterial infusion chemotherapy plus lenvatinib vs lenvatinib alone in advanced hepatocellular carcinoma
ChiCTR2100045744Phase 3Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Progression-free survival, Enhanced CT or MR examination of the upper abdomen and 2 more. Started Jul 2021; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100045744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045744.